PIH22 Cost-Effectiveness Analysis of Use of Dydrogesterone in Premenstrual Syndrome  by Kolbin, A. et al.
A508  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
PIH23
Cost-BenefIt Model of VaryIng nexPlanon and otHer long-aCtIng 
reVersIBle ContraCePtIVe (larC) MetHods: UPtake CoMPared to tHe 
oral ContraCePtIVe PIll: Uk PersPeCtIVe
Praet C., D’Oca K.
Merck Sharp and Dohme Ltd, Hoddesdon, UK
Objectives: Cost is considered one of the major barriers to greater use of LARC 
(Long-Acting Reversible Contraceptive) methods, especially cost of treatment initia-
tion. However, when considering their contraceptive efficacy alongside cost of preg-
nancy, LARC methods are deemed by NICE to be more cost-effective than combined 
oral contraceptive pills even at one year of use. (NICE LARC CG30 2005). MethOds: 
A 3 year time-horizon cost-benefit model was developed to assess budgetary impact 
of increasing LARC uptake (implant, IUD, IUS and injectable) compared to the oral 
contraceptive pill, in UK women aged 16-49 who currently use the following con-
traceptives of interest: non-LARC method (defined as contraceptive pill only) or 
LARC methods (IUD, IUS, injectable, implant). A weighted-average price based on 
current market shares was calculated, for all contraceptive pills currently available 
in the UK. Increased uptake of any LARC method was offset against a reduction in 
contraceptive pill usage. Unintended pregnancies, based on typical failure rate, 
occurring with all treatments considered was taken into account. Results: Of 
approximately 14,750,000 women aged 16-49 in the UK, official statistics confirm 
37% use contraceptive methods of interest to our model. This proportion formed 
our cohort of approximately 5,500,000 UK women aged 16-49, which was followed 
over a 3 year time horizon. A 100% increase in uptake of each LARC method would 
lead to a 49% decrease in oral contraceptive pill uptake. Over a three year period 
this would save 374,794 unintended pregnancies, and elicit financial savings of 
£630,831,022, on which £54,098,847 is attributable to treatment costs (ingredient, 
consultations, removal/insertion costs) and £576,732,175 to the cost of unintended 
pregnancies (live birth, miscarriage, abortion, ectopic pregnancy). cOnclusiOns: 
The model projects that increasing LARC uptake will result in a significant reduc-
tion in the number of unintended pregnancies, with consequent savings to the 
NHS across the UK.
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Objectives: Our aim was to assess the costs and consequences of labour induction 
using misoprostol vaginal insert (MVI) compared with currently used technologies 
using a specifically developed user-friendly decision model developed for Austria, 
Poland, Romania, Russia and Slovakia. MethOds: The model was developed in 
Microsoft Office Excel and compares clinical and safety aspects like time to vaginal 
delivery, time to active labour, occurrence of cesarean delivery and adverse events 
of MVI with selected comparators. Efficacy and safety data were retrieved from tar-
geted literature review, conducted in the main medical databases. Country-specific 
information about costs and resource use was incorporated into the model. Local 
data were collected for each country via a specifically developed questionnaire. The 
model considered the hospital and public payer perspectives. The model gener-
ated results as an incremental difference between the total costs related to labour 
induction with MVI or a comparator. The threshold price of MVI was also calcu-
lated. Results: Local Key Opinion Leaders recommended the following compara-
tors: dinoprostone vaginal insert (DVI; Austria), dinoprostone vaginal tablets (Dtab; 
Austria, Slovakia), dinoprostone cervical gel (Dgel; Poland, Russia, Slovakia) and 
oxytocin (Austria, Poland, Romania, Russia). The hospital perspective was chosen 
as default (additionally the public payer perspective was adopted for 2 countries). 
The use of MVI in most scenarios is related to a reduction in time consumption of 
hospital staff and in the length of patients’ stay in hospital wards. MVI was less 
costly or marginally more expensive in 80% of cases. cOnclusiOns: Induction of 
labour with the use of MVI using a hospital perspective, brought savings in most 
countries and scenarios in comparison to other prostaglandins (DVI, Dtab, Dgel).
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Objectives: Herpes Zoster is a very painful and debilitating disease for which no 
satisfactory treatment exist. A vaccine is licensed in Europe for the prevention of 
Herpes Zoster (HZ) and postherpetic neuralgia (PHN) in adults aged ≥ 50 years and 
is recommended in France and UK. The objective of this study was to assess the 
cost-effectiveness of vaccination programs in people aged 65 years and over in 
Norway. MethOds: An existing European Markov cohort Model was adapted to 
the Norwegian health care setting. Health states considered are healthy, HZ, PHN, 
healthy post-HZ and death. HZ and PHN states are further split by pain severity 
(mild, moderate or severe). A vaccine efficacy durability model based on the pivotal 
trial data was included to simulate waning in the efficacy. The cost-effectiveness 
outcomes were assessed from both the third party payer and the societal perspec-
tive. First, analysis comparing a HZ vaccination policy for adults aged ≥ 65 years with 
a no vaccination policy was done. Then, analysis comparing vaccination policies 
of 5-years age class cohorts (from 65 to 100 years old) to a no vaccination policy 
were conducted. Input data were obtained from Norwegian sources whenever avail-
Objectives: Although the relationship between use of glucocorticoids (GC) and 
occurrence of adverse events (AE) is widely acknowledged, the estimation of risk 
size of specific AE is still imprecise. The aim of study was to quantify the incidence 
and economic cost of selected steroid-related AE in GC-users regardless of baseline 
chronic disease. MethOds: Review of the available data about the consequences 
of long-term use of oral GC (depending on prednisone or its equivalent dose and 
period of use) was conducted. From 162 full-text publications (10024 abstracts), 
four with mixed population and > 5 years median follow–up were valuable. Hip 
fracture (HFr), cataract (CAT) and diabetes mellitus (DM) were chosen as the com-
mon and most cost generating AE connected with oral GC treatment. A Markov 
model with a lifetime horizon (30 years) was developed to forecast incidence 
and health care cost of three regimen (non-GC, low dose GC < 2.5 mg, high dose 
GC > 7.5 mg). Direct medical costs were included in the analysis. Results: For a 
lifetime horizon the incidence of HFr, CAT and DM increased from 0.77% to 5.49%, 
23.48% to 91.04% and 12.34% to 17.02% (7.1, 3.9, 1.4 fold increase) respectively for 
comparison non-GC versus high dose GC. For selected cohort of 1,000 you need to 
treat 34, 2, 22 patients respectively (low dose GC instead of high dose GC) to prevent 
one additional case of HFr, CAT, DM. Shorter duration of steroid therapy (5 years) 
provide two Quality-Adjusted Life Months gained (per one patient) and leads to 
2,230, 35,460, 6,920 avoided cases of HFr, CAT, DM (per 100,000 cohort). The use 
of low-dose or non-GC is cost-effective strategy (total cost per patient 2,958 PLN, 
1,301 PLN, respectively) compared with high-dose GC (10,823 PLN). cOnclusiOns: 
Oral GC treatment can lead to dose-dependent increase in the risk of selected AE.
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Objectives: Some drugs increase risk for adverse effects in elderly patients. 
Accordingly, lists of potentially inappropriate medication (PIM) that should be 
avoided in elderly patients have been proposed. In 2010 an expert panel published 
a PIM list adapted to the German drug market (PRISCUS-list) which lists 83 inappro-
priate agents and their recommended surrogates. This study calculates the amount 
of drug reimbursement of PIM and the potential saving using appropriate surrogates 
recommended by the PRISCUS list from the perspective of statutory health insur-
ance (SHI). MethOds: Data was provided by AOK Research Institute (WIdO). Study 
material consists of a register extraction of the top 30 drugs (by sales) on PRISCUS-
list in 2009 for patients ≥ 65 years of the entire SHI-population. We calculated the 
percentage of sales and defined daily doses (DDD) for patients ≥ 65 compared to 
the total SHI-population. Costs for the recommended substitution were estimated 
by different scenarios. Results: In 2009, the proportion of the top 30 drugs on 
the PRISCUS-list that were prescribed to patients ≥ 65 was 58.2%. Sotalol was the 
drug with the largest proportion of DDD prescribed to patients ≥ 65 (92.9%). Drug 
reimbursement for the top 30 PIM medications prescribed to patients ≥ 65 were 
€ 305.7 million (54.3% of total reimbursement). Reimbursement for Solifenacin was 
highest with € 32.5 million. Prescription of the surrogates would lead to increasing 
costs for the German health care system. Those were calculated to range between 
€ 325.9 million and € 810.0 million. cOnclusiOns: This is the first study assessing 
the economic burden of PIM according to PRISCUS-list in Germany. The results show 
that a more appropriate medication for the elderly comes along with additional 
costs. For a final evaluation of relevance and economics of PIM, costs of adverse 
drug events caused by PIM and clinical feasibility of substitution have to be taken 
into consideration.
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Objectives: The primary objective of the study was the analysis of pharmaco-
economic expediency of administration of dydrogesterone (Duphaston®) for 
premenstrual syndrome (PMS) treatment in comparison with micronized pro-
gesterone (Utrogestan®). MethOds: The mathematical modeling with dydroges-
terone or micronized progesterone was applied in the study. For the calculation 
of the efficacy data of clinical trials were used. Costs were calculated on the basis 
of Russian prices (grls. rosminzdrav. ru). The model was constructed as follow-
ing: for each branch of the decision tree, cost and efficacy for a group of 100 
patients (female aged 18 – 45 years) and per patient were analyzed. Modeling 
duration was 3 months (therapy during three cycles). The cost-effectiveness ratio 
(CER) and incremental cost-effectiveness ratio (ICERs) were calculated. Results 
were evaluated to cost-effectiveness threshold. Efficiency was estimated on 
the basis of clinical trials (effectiveness). Calculation of cost included: the cost 
of drugs administration course; costs of consultative and diagnostic appoint-
ments of the gynecologist; the cost of inefficient therapy – costs of additional 
diagnostic examination. The comprehensive sensitivity analysis was per-
formed. Results: The cost of the total course of therapy with dydrogesterone 
was more expensive in comparison with micronized progesterone – 84,1 EUR 
against 82,6 EUR. Strategy of administration of dydrogesterone showed more 
efficiency in comparison with micronized progesteron (8% increase of effective-
ness). CER for dydrogesterone and micronized progesterone were 115.20 and 
127.07 respectively. The ICER was 18.75 Eur per patient that is much lower than 
a cost-effectiveness threshold in Russia (27922.8 EUR). The sensitivity analysis 
confirmed conclusions of the main scenario. cOnclusiOns: The strat-
egy of administration of dydrogesterone in PMS is economically expedient 
from the point of view of cost-effectiveness ratio. In addition, increase of effec-
tiveness was noted for use of dydrogesterone. The study was conducted at Abbott 
support.
